IDiyas

For the Inventor, By the Inventor

Belmont, MA, United States of America

Rima Kaddurah-Daouk

USPTO Granted Patents = 29 

Average Co-Inventor Count = 2.1

ph-index = 13

Forward Citations = 400(Granted Patents)


Location History:

  • Watertown, MA (US) (1994)
  • Belmont, MA (US) (1997 - 2021)

Company Filing History:

goldMedal10 out of 53 
 
Metabolon, Inc.
 patents
silverMedal10 out of 1,521 
 
Cornell Research Foundation Inc.
 patents
bronzeMedal4 out of 1,206 
 
Dana-farber-cancer Institute Inc.
 patents
4. 4 out of 4 
 
Avicena Group, Inc.
 patents
5. 4 out of 2,007 
 
Duke University
 patents
6. 3 out of 3 
 
Amira, Inc.
 patents
7. 2 out of 915 
 
University of Chicago
 patents
8. 2 out of 3 
 
Lipomics Technologies, Inc.
 patents
9. 2 out of 1,742 
 
Mayo Foundation for Medical Education and Research
 patents
10. 1 out of 1 
 
Matabolon, Inc.
 patent
11. 1 out of 1 
 
Fal Diagnostics
 patent
12. 1 out of 2,882 
 
The General Hospital Corporation
 patents
13. 1 out of 76 
 
Children's Hospital Research Center at Oakland
 patents
14. 1 out of 14 
 
Ixcela, Inc.
 patents
15. 5 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1994-2021

Loading Chart...
29 patents (USPTO):Explore Patents
1. 11122997 - Modulating the aryl hydrocarbon receptor system to treat major depressive disorder (2021-09-21),
2. 8637321 - Lipidomics approaches for central nervous system disorders (2014-01-28),
3. 8394354 - Biomarkers for depression and methods using the same (2013-03-12),
4. 8137977 - Lipidomic approaches to determining drug response phenotypes in cardiovascular disease (2012-03-20),
5. 7947453 - Methods for drug discovery, disease treatment, and diagnosis using metabolomics (2011-05-24),
6. 7910301 - Methods for drug discovery, disease treatment, and diagnosis using metabolomics (2011-03-22),
7. 7682784 - Methods for drug discovery disease treatment, and diagnosis using metabolomics (2010-03-23),
8. 7682783 - Methods for drug discovery, disease treatment, and diagnosis using metabolomics (2010-03-23),
9. 7635556 - Methods for drug discovery, disease treatment, and diagnosis using metabolomics (2009-12-22),
10. 7556935 - Induction of apoptosis by cellular stress (2009-07-07),
11. 7553616 - Methods for drug discovery, disease treatment, and diagnosis using metabolomics (2009-06-30),
12. 7550260 - Methods for drug discovery, disease treatment, and diagnosis using metabolomics (2009-06-23),
13. 7550258 - Methods for drug discovery, disease treatment, and diagnosis using metabolomics (2009-06-23),
14. 7329489 - Methods for drug discovery, disease treatment, and diagnosis using metabolomics (2008-02-12),
15. 7285573 - Use of creatine or creatine analogs for the treatment of diseases of the nervous system (2007-10-23),

Certainly! Here is the article about inventor Rima Kaddurah-Daouk based on the provided data:

Title: Innovator Spotlight: Rima Kaddurah-Daouk - Pioneering Solutions for CNS Disorders

Introduction:

Rima Kaddurah-Daouk, a distinguished inventor based in Belmont, MA, has made significant contributions to the field of central nervous system (CNS) disorders with an impressive portfolio of 29 patents. His groundbreaking work has focused on leveraging lipidomics to revolutionize the diagnosis and treatment of major depressive disorder and other CNS ailments.

Latest Patents:

1. Modulating the Aryl Hydrocarbon Receptor System to Treat Major Depressive Disorder: This patent introduces innovative methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system, offering new avenues for therapeutic interventions.

2. Lipidomics Approaches for Central Nervous System Disorders: This patent showcases the power of lipidomics in profiling lipid metabolites for characterizing changes in lipid metabolism related to CNS disorders, facilitating personalized therapeutic approaches and drug design.

Career Highlights:

Throughout his career, Rima Kaddurah-Daouk has demonstrated a commitment to advancing the understanding and treatment of CNS disorders. His tenure at companies like Metabolon, Inc. and Cornell Research Foundation Inc. has been marked by a relentless pursuit of innovation and excellence in research.

Collaborations:

Rima Kaddurah-Daouk has collaborated with esteemed professionals in the field, including Bruce S Kristal and Donald W Kufe, to pioneer groundbreaking solutions for CNS disorders. These collaborations have led to significant advancements in lipidomics and personalized medicine approaches for improved patient outcomes.

Conclusion:

In conclusion, Rima Kaddurah-Daouk's relentless dedication to innovation and his pioneering work in lipidomics have positioned him as a trailblazer in the field of CNS disorders. His patents and collaborations underscore his commitment to transforming the landscape of therapeutic interventions for complex neurological conditions, offering hope for enhanced treatments and better outcomes for patients worldwide.

If you need more information or have any other requests, feel free to ask!

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…